RAFAEL HOLDINGS, INC. Business Acquisition, Transaction Costs
RAFAEL HOLDINGS, INC. (RFL) had Business Acquisition, Transaction Costs of $1.20 million as of 2024-10-31, per its 10-Q filed 2025-12-12.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2025-12-12
- 2024-10-31: Business Acquisition, Transaction Costs $1.20M.
- 2023-01-31: Business Acquisition, Transaction Costs $1.20M.
- 2022-10-31: Business Acquisition, Transaction Costs $1.20M.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2024-10-31 | $1.20M 10-Q · filed 2025-12-12 |
| 2023-01-31 | $1.20M 10-Q · filed 2023-06-13 |
| 2022-10-31 | $1.20M 10-Q · filed 2022-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |